The RSUs vest over four years, with 25% of the shares vesting on each anniversary of the grant date, subject to the new ...
The RSUs vest over four years, with 25% of the shares vesting on each anniversary of the grant date, subject to the new employee’s continued service relationship with Travere through the applicable ...
Travere Therapeutics was first featured on our site on August 14, 2024, when the stock was trading at $8.91. At the time, our ...
The FDA’s Office of Prescription Drug Promotion sent Travere Therapeutics a letter over its advertising for Filspari, a drug that’s approved to slow kidney function decline in people with primary IgA ...
Biotech name Travere Therapeutics is not profitable yet but a turnaround may be around the corner as the stock hovers in a ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
The "Focal Segmental Glomerulosclerosis - Market Insight, Epidemiology, Forecast - 2036" has been added to ResearchAndMarkets.com's offering. The report provides an in-depth assessment of FSGS ...
For 2Q26, Nomura Smid Cap Core Fund Institutional Class shares performed in-line with the Fund's benchmark, the Russell 2500 ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Track conference calls, annual meetings, summits, analyst days and other corporate events scheduled for Travere Therapeutics Inc. Use the full market events calendar to scan activity across all ...
Pricing for ETFs is the latest price and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results